Rapid selection and archiving of mutation E157Q in HIV-1 DNA during short-term low-level replication on a raltegravir-containing regimen

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 2, 2009, Pages 433-434

  Ghosn, Jade ^a,b   Mazet, Anne Aurélie ^b   Avettand Fenoel, Véronique ^a   Peytavin, Gilles ^c   Wirden, Marc ^d   Delfraissy, Jean François ^b   Chaix, Marie Laure ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b BICÊTRE HOSPITAL   (France)

^c BICHAT HOSPITAL   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Antiretroviral therapy; HIV; Resistance

Indexed keywords

ABACAVIR; ATAZANAVIR; CD4 ANTIGEN; DARUNAVIR; INTEGRASE; LAMIVUDINE; RALTEGRAVIR; RITONAVIR; TENOFOVIR; TIPRANAVIR; VIRUS DNA; VIRUS RNA;

ADULT; ANTIVIRAL RESISTANCE; CASE REPORT; DOSE RESPONSE; DRUG TREATMENT FAILURE; GENE AMPLIFICATION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LETTER; LOW DRUG DOSE; MALE; PATIENT COMPLIANCE; PATIENT MONITORING; PHARMACOGENETICS; VIRUS REPLICATION;

AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV INTEGRASE; HIV-1; HUMANS; MALE; MUTATION, MISSENSE; PYRROLIDINONES; SELECTION (GENETICS);

EID: 67650763493     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp182     Document Type: Letter

References (8)

1. Steigbigel RT, Cooper DA, Kumar PN et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359: 339-54.
2. Grinsztejn B, Nguyen BY, Katlama C et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: A phase II randomised controlled trial. Lancet 2007; 369: 1261-9.
3. Cooper DA, Steigbigel RT, Gatell JM et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359: 355-65.
4. Ghosn J, Viard JP, Katlama C et al. Evidence of genotypic resistance diversity of archived and circulating viral strains in blood and semen of pre-treated HIV-infected men. AIDS 2004; 18: 447-57.
5. Ghosn J, Pellegrin I, Goujard C et al. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS 2006; 20: 159-70.
6. Katlama C, Caby F, Andrade RM et al. Virological evolution of HIV treatment-experienced patients with raltegravir-based salvage regimens. Antivir Ther 2008; 13 Suppl 3: A13.
7. Kuiken C, Leitner T, Foley B et al. HIV Sequence Compendium. Los Alamos, NM, USA: Theoretical Biology and Biophysics, 2008; 328.
8. Malet I, Delelis O, Valantin MA et al. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother 2008; 52: 1351-8.